TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock Has Average Price Target of $10.20

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have been assigned an average rating of “Hold” from the five analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $10.20.

A number of equities research analysts recently issued reports on TLSI shares. Zacks Research raised shares of TriSalus Life Sciences to a “hold” rating in a research note on Thursday, September 10th. Guggenheim set a $12.00 price objective on shares of TriSalus Life Sciences in a research note on Wednesday, September 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Friday, August 7th. Stifel Nicolaus set a $12.00 target price on shares of TriSalus Life Sciences in a report on Wednesday, September 23rd. Finally, Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd.

TriSalus Life Sciences Stock Performance

NASDAQ:TLSI opened at $4.27 on Friday. The company has a market cap of $262.93 million, a price-to-earnings ratio of -3.28 and a beta of 0.47. TriSalus Life Sciences has a 1 year low of $2.20 and a 1 year high of $7.95. The stock’s 50 day simple moving average is $4.90 and its two-hundred day simple moving average is $4.33. The company has a debt-to-equity ratio of 5.05, a current ratio of 5.35 and a quick ratio of 4.97.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16). The firm had revenue of $11.41 million for the quarter, compared to the consensus estimate of $10.27 million. As a group, equities analysts anticipate that TriSalus Life Sciences will post -0.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TriSalus Life Sciences

Several large investors have recently added to or reduced their stakes in TLSI. State Street Corp boosted its holdings in shares of TriSalus Life Sciences by 86.3% in the 2nd quarter. State Street Corp now owns 610,963 shares of the company’s stock worth $2,780,000 after purchasing an additional 282,943 shares during the period. BlackRock Inc. purchased a new stake in TriSalus Life Sciences during the 2nd quarter valued at $12,099,000. Nantahala Capital Management LLC purchased a new stake in TriSalus Life Sciences during the 2nd quarter valued at $4,550,000. First Light Asset Management LLC bought a new stake in TriSalus Life Sciences in the first quarter worth $20,267,000. Finally, Perkins Capital Management Inc. bought a new stake in TriSalus Life Sciences in the first quarter worth $920,000. 2.58% of the stock is owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is an oncology-focused life sciences company developing medical technologies and therapies for patients with difficult-to-treat liver and pancreatic tumors. The company’s approach is designed to address the unique biological and physical barriers that can limit the delivery of cancer treatments to solid tumors.

TriSalus’ principal technology is its Pressure-Enabled Drug Delivery (PEDD) platform, which is intended to improve the distribution of therapeutic agents within tumors through regional infusion.